Your browser doesn't support javascript.
loading
The HLA-II immunopeptidome of SARS-CoV-2.
Weingarten-Gabbay, Shira; Chen, Da-Yuan; Sarkizova, Siranush; Taylor, Hannah B; Gentili, Matteo; Hernandez, Gabrielle M; Pearlman, Leah R; Bauer, Matthew R; Rice, Charles M; Clauser, Karl R; Hacohen, Nir; Carr, Steven A; Abelin, Jennifer G; Saeed, Mohsan; Sabeti, Pardis C.
Afiliación
  • Weingarten-Gabbay S; Broad Institute of MIT and Harvard University, Cambridge, MA, USA; Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA, USA; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA. Electronic address: shirawg@broadinstitute.org.
  • Chen DY; Department of Biochemistry & Cell Biology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA; National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
  • Sarkizova S; Broad Institute of MIT and Harvard University, Cambridge, MA, USA.
  • Taylor HB; Broad Institute of MIT and Harvard University, Cambridge, MA, USA.
  • Gentili M; Broad Institute of MIT and Harvard University, Cambridge, MA, USA.
  • Hernandez GM; Broad Institute of MIT and Harvard University, Cambridge, MA, USA.
  • Pearlman LR; Broad Institute of MIT and Harvard University, Cambridge, MA, USA.
  • Bauer MR; Harvard Program in Biological and Biomedical Sciences, Division of Medical Sciences, Harvard University Medical School, Boston, MA, USA.
  • Rice CM; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
  • Clauser KR; Broad Institute of MIT and Harvard University, Cambridge, MA, USA.
  • Hacohen N; Broad Institute of MIT and Harvard University, Cambridge, MA, USA; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA; Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
  • Carr SA; Broad Institute of MIT and Harvard University, Cambridge, MA, USA.
  • Abelin JG; Broad Institute of MIT and Harvard University, Cambridge, MA, USA.
  • Saeed M; Department of Biochemistry & Cell Biology, Boston University Chobanian and Avedisian School of Medicine, Boston, MA, USA; National Emerging Infectious Diseases Laboratories, Boston University, Boston, MA, USA.
  • Sabeti PC; Broad Institute of MIT and Harvard University, Cambridge, MA, USA; Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA, USA; Massachusetts Consortium on Pathogen Readiness, Boston, MA, USA; Department of Immunology and Infectious Disease, Harvard T.H. Chan School of
Cell Rep ; 43(1): 113596, 2024 01 23.
Article en En | MEDLINE | ID: mdl-38117652
ABSTRACT
Targeted synthetic vaccines have the potential to transform our response to viral outbreaks, yet the design of these vaccines requires a comprehensive knowledge of viral immunogens. Here, we report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) peptides that are naturally processed and loaded onto human leukocyte antigen-II (HLA-II) complexes in infected cells. We identify over 500 unique viral peptides from canonical proteins as well as from overlapping internal open reading frames. Most HLA-II peptides colocalize with known CD4+ T cell epitopes in coronavirus disease 2019 patients, including 2 reported immunodominant regions in the SARS-CoV-2 membrane protein. Overall, our analyses show that HLA-I and HLA-II pathways target distinct viral proteins, with the structural proteins accounting for most of the HLA-II peptidome and nonstructural and noncanonical proteins accounting for the majority of the HLA-I peptidome. These findings highlight the need for a vaccine design that incorporates multiple viral elements harboring CD4+ and CD8+ T cell epitopes to maximize vaccine effectiveness.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Revista: Cell Rep Año: 2024 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 Límite: Humans Idioma: En Revista: Cell Rep Año: 2024 Tipo del documento: Article